<DOC>
	<DOCNO>NCT02435680</DOCNO>
	<brief_summary>To determine whether MCS110 antibody therapy improve efficacy carboplatin gemcitabine ( carbo/gem ) advance TNBC patient</brief_summary>
	<brief_title>Efficacy Study MCS110 Given With Carboplatin Gemcitabine Advanced Triple Negative Breast Cancer ( TNBC )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Adult woman ( ≥ 18 year age ) advance TNBC . Histological cytological evidence estrogenreceptor negative ( ER ) , progesterone receptor negative ( PgR ) human epidermal growth factor2 receptor negative ( HER2 ) Breast Cancer local laboratory testing , base last available tumor tissue . ER/PgR negativity follow local guideline If IHC HER2 2+ , negative FISH test require A pretreatment tumor biopsy demonstrate high TAM content assess per central laboratory Patients must : At least one measurable lesion per RECIST 1.1 . ( Note : Measurable lesion include lytic mixed ( lytic + blastic ) bone lesion , identifiable soft tissue component meet measurability criterion ) Prior chemotherapy advance BC . Previous adjuvant/neoadjuvant chemotherapy allow ( carboplatin , cisplatin gemcitabine &gt; 12 month pass since last administration ) . Therapy underlying malignancy within 2 week prior start study treatment : Chemotherapy , biologic therapy ( antibody biologically target small molecule ) Radiotherapy Major surgery Patients receive concomitant immunosuppressive agent chronic corticosteroid ( ≥10 mg prednisone equivalent ) time first study dose . Clinically significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month screen . Known history human immunodeficiency virus active infection hepatitis virus uncontrolled active systemic infection . Patients follow laboratory value screen Day 1 predose : Absolute Neutrophil Count ( ANC ) &lt; 1.5x109/L Hemoglobin &lt; 9 g/dL Platelets &lt; 100x109/L Serum creatinine &gt; 1.5 x ULN Serum total bilirubin &gt; 1.5 x ULN AST/SGOT ALT/SGPT &gt; 3.0 x ULN</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MCS110 ; carboplatin ; gemcitabine ; TNBC ; TAMs</keyword>
</DOC>